November 2026

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI ()
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke ()
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M ()
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter ()
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short ()
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary? ()
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues ()
October's Top Stories: Siemens Healthineers changes course | Defibrillation leads recalled | The world’s best heart hospitals ()
TAVR linked to key benefits for select heart patients with moderate AS | Degenerative mitral valve disease | New HF data ()
News Alert: TAVR linked to key benefits for select heart patients with moderate aortic stenosis ()
Heart medication may be a ‘wonder drug’ | New EARLY TAVR data | Abbott kicks off trial | Cardiologist wins award | TTVR research ()